Compare · COR vs HKPD
COR vs HKPD
Side-by-side comparison of Cencora Inc. (COR) and Cellyan Biotechnology Co. Ltd (HKPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and HKPD operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $68.51B, about 17150.8x HKPD ($4.0M).
- COR has been more active in the news (24 items in the past 4 weeks vs 3 for HKPD).
- COR has more recent analyst coverage (25 ratings vs 0 for HKPD).
- Company
- Cencora Inc.
- Cellyan Biotechnology Co. Ltd
- Price
- -
- -
- Market cap
- $68.51B
- $4.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 24
- 3
- Recent ratings
- 25
- 0
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
Latest COR
- President & CEO Mauch Robert P. was granted 18,292 restricted stock units (SEC Form 4)
- Executive Vice President Campbell Elizabeth S was granted 4,402 restricted stock units (SEC Form 4)
- Chief Financial Officer Boratto Eva C was granted 5,488 restricted stock units (SEC Form 4)
- SVP & Chief Accounting Officer Krikorian Lazarus was granted 3,216 restricted stock units (SEC Form 4)
- EVP, Chief Data & Info Officer Verma Pawan was granted 4,231 restricted stock units (SEC Form 4)
- President & CEO Mauch Robert P. converted options into 40,271 shares and covered exercise/tax liability with 17,405 shares, increasing direct ownership by 34% to 90,652 units (SEC Form 4) (tax liability)
- SVP & Chief Accounting Officer Krikorian Lazarus converted options into 3,386 shares and covered exercise/tax liability with 1,457 shares, increasing direct ownership by 13% to 16,948 units (SEC Form 4) (withholding tax)
- Executive Vice President Campbell Elizabeth S converted options into 17,190 shares and covered exercise/tax liability with 7,947 shares, increasing direct ownership by 45% to 29,682 units (SEC Form 4) (for withholding tax)
- EVP, Chief Data & Info Officer Verma Pawan converted options into 1,321 shares and covered exercise/tax liability with 676 shares, increasing direct ownership by 7% to 10,077 units (SEC Form 4) to satisfy tax liability
- President & CEO Mauch Robert P. converted options into 4,066 shares and covered exercise/tax liability with 1,673 shares, increasing direct ownership by 4% to 67,786 units (SEC Form 4) (for withholding tax)
Latest HKPD
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form S-8 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 20-F filed by Cellyan Biotechnology Co. Ltd
- SEC Form NT 20-F filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd